These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38716401)

  • 41. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
    McSorley JC; Reyes D; Tonna I; Bateman V
    Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
    Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
    Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dalbavancin as a Viable Alternative for Addressing Treatment Adherence in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: A Case Report.
    Sabina M; Cobian J; Dibo I
    Cureus; 2024 Feb; 16(2):e54078. PubMed ID: 38481906
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dalbavancin: a review.
    Scheinfeld N
    Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective Cohort Study of Infective Endocarditis in People Who Inject Drugs.
    Pericàs JM; Llopis J; Athan E; Hernández-Meneses M; Hannan MM; Murdoch DR; Kanafani Z; Freiberger T; Strahilevitz J; Fernández-Hidalgo N; Lamas C; Durante-Mangoni E; Tattevin P; Nacinovich F; Chu VH; Miró JM;
    J Am Coll Cardiol; 2021 Feb; 77(5):544-555. PubMed ID: 33538252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dalbavancin in catheter-related bloodstream infections: a pilot study.
    Venturini S; Reffo I; Avolio M; Basaglia G; Del Fabro G; Callegari A; Grembiale A; Garlatti E; Castaldo V; Tonizzo M; Balbi M; Cevolani M; Basso B; Pellis T; Crapis M
    Infez Med; 2023; 31(2):250-256. PubMed ID: 37283643
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clonal expansion of community-associated meticillin-resistant Staphylococcus aureus (MRSA) in people who inject drugs (PWID): prevalence, risk factors and molecular epidemiology, Bristol, United Kingdom, 2012 to 2017.
    Packer S; Pichon B; Thompson S; Neale J; Njoroge J; Kwiatkowska RM; Oliver I; Telfer M; Doumith M; Buunaaisie C; Heinsbroek E; Hopewell-Kelly N; Desai M; Hope V; Williams OM; Kearns A; Hickman M; Gobin M
    Euro Surveill; 2019 Mar; 24(13):. PubMed ID: 30940316
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dalbavancin Use for the Treatment of Methicillin-resistant
    Barber KE; Tirmizi A; Finley R; Stover KR
    J Pharmacol Pharmacother; 2017; 8(2):77-79. PubMed ID: 28706403
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study.
    Hervochon C; Hennart B; Leroy AG; Corvec S; Boutoille D; Senneville É; Sotto A; Illes G; Chavanet P; Dubée V; Bleibtreu A; De Carné MC; Talarmin JP; Revest M; Castan B; Bellouard R; Dailly É; Allorge D; Dinh A; Le Turnier P; Gregoire M;
    J Antimicrob Chemother; 2023 Dec; 78(12):2919-2925. PubMed ID: 37864551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The current and future off-label uses of dalbavancin: a narrative review.
    De Vito A; Fiore V; Colpani A; Zauli B; Fanelli C; Tiseo G; Occhineri S; Babudieri S; Falcone M; Madeddu G
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1222-1238. PubMed ID: 36808371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness, safety and cost analysis of dalbavancin in clinical practice.
    Arrieta-Loitegui M; Caro-Teller JM; Ortiz-Pérez S; López-Medrano F; San Juan-Garrido R; Ferrari-Piquero JM
    Eur J Hosp Pharm; 2022 Jan; 29(1):55-58. PubMed ID: 33020060
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and safety of dalbavancin in France: a prospective, multicentre cohort study.
    Courjon J; Senneville E; Illes HG; Pavese P; Boutoille D; Daoud FC; Dunkel N; Tattevin P
    Int J Antimicrob Agents; 2023 Oct; 62(4):106945. PubMed ID: 37543122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis.
    Monteagudo-Martínez N; Solís-García Del Pozo J; Nava E; Ikuta I; Galindo M; Jordán J
    Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1477-1489. PubMed ID: 32981375
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data.
    Wilke M; Worf K; Preisendörfer B; Heinlein W; Kast T; Bodmann KF
    GMS Infect Dis; 2019; 7():Doc03. PubMed ID: 31728264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
    Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
    Trials; 2022 May; 23(1):407. PubMed ID: 35578360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.
    Matt M; Duran C; Courjon J; Lotte R; Moing VL; Monnin B; Pavese P; Chavanet P; Khatchatourian L; Tattevin P; Cattoir V; Lechiche C; Illes G; Lacassin-Beller F; Senneville E; Dinh A;
    J Glob Antimicrob Resist; 2021 Jun; 25():341-345. PubMed ID: 33962065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
    Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
    Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dalbavancin in clinical practice in Spain: a 2 year retrospective study.
    Morata L; Aguado JM; Salavert M; Pasquau J; Míguez E; Muñoz P; Rosselló I; Almirante B
    JAC Antimicrob Resist; 2022 Dec; 4(6):dlac120. PubMed ID: 36570687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections.
    Sivori F; Cavallo I; Kovacs D; Guembe M; Sperduti I; Truglio M; Pasqua M; Prignano G; Mastrofrancesco A; Toma L; Pimpinelli F; Morrone A; Ensoli F; Di Domenico EG
    Microbiol Spectr; 2022 Apr; 10(2):e0035122. PubMed ID: 35416701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.